Special Topic: Progress and Challenges in Vaccinology Development of a Vaccine Against Pandemic Influenza Viruses: Current Status and Perspectives

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.

  2008influential reference
• Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response.

  2008cited by this paper
• Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

  2008cited by this paper
• Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol.

  2008influential reference
• Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

  2008cited by this paper
• Failed HIV vaccine may have increased vulnerability to infection.

  2008cited by this paper
• Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.

  2008cited by this paper
• Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models.

  2008cited by this paper
• Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.

  2008cited by this paper
• Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

  2008cited by this paper
• Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.

  2008cited by this paper
• Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

  2008cited by this paper
• The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

  2008cited by this paper
• Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.

  2007cited by this paper
• Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.

  2007influential reference
• Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

  2007cited by this paper
• The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology

  2007influential reference
• Changing perspective on immunization against influenza.

  2007cited by this paper
• Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine.

  2007cited by this paper
• Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge

  2007cited by this paper
• Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.

  2007cited by this paper
• Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

  2007influential reference
• Toxicity of Influenza A Virus Matrix Protein 2 for Mammalian Cells is Associated with its Intrinsic Proton-Channeling Activity

  2007cited by this paper
• Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.

  2007cited by this paper
• HIV vaccine failure prompts Merck to halt trial

  2007cited by this paper
• Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.

  2007cited by this paper
• Avian and pandemic influenza: an overview.

  2007influential reference
• Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1

  2007cited by this paper
• A New Generation of Modified Live-Attenuated Avian Influenza Viruses Using a Two-Strategy Combination as Potential Vaccine Candidates

  2007cited by this paper
• GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

  2007cited by this paper
• Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein.

  2007cited by this paper
• The threat of avian influenza A (H5N1). Part IV: development of vaccines

  2007cited by this paper
• MF59 Is a Safe and Potent Vaccine Adjuvant for Flu Vaccines in Humans: What Did We Learn During Its Development?

  2007cited by this paper
• A Novel Intranasal Virus-Like Particle (VLP) Vaccine Designed to Protect against the Pandemic 1918 Influenza A Virus (H1N1)

  2007cited by this paper
• Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.

  2007cited by this paper
• [Tetravaccine--new fundamental approach to prevention of influenza pandemic].

  2007cited by this paper
• Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

  2007cited by this paper
• Influenza vaccine: the challenge of antigenic drift.

  2007cited by this paper
• Novel Approach to the Development of Effective H5N1 Influenza A Virus Vaccines: Use of M2 Cytoplasmic Tail Mutants

  2007cited by this paper
• Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.

  2007cited by this paper
• Making Better Influenza Virus Vaccines?

  2006influential reference
• Vaccines for seasonal and pandemic influenza.

  2006influential reference
• Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.

  2006cited by this paper
• Vaccination of Pigs against Swine Influenza Viruses by Using an NS1-Truncated Modified Live-Virus Vaccine

  2006cited by this paper
• H5N1 influenza--continuing evolution and spread.

  2006cited by this paper
• Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses

  2006cited by this paper
• Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

  2006cited by this paper
• Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets

  2006cited by this paper
• Distinct Domains of the Influenza A Virus M2 Protein Cytoplasmic Tail Mediate Binding to the M1 Protein and Facilitate Infectious Virus Production

  2006cited by this paper
• Development of vaccines against influenza H5.

  2006cited by this paper
• Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers

  2006cited by this paper
• Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.

  2006cited by this paper
• Vaccines for Pandemic Influenza

  2006influential reference
• Pandemic Influenza Threat and Preparedness

  2006cited by this paper
• Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza.

  2006cited by this paper
• Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

  2006cited by this paper
• Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

  2006influential reference
• Influenza and the challenge for immunology

  2006cited by this paper
• The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.

  2006cited by this paper
• Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.

  2006cited by this paper
• Emergence and predominance of an H5N1 influenza variant in China

  2006cited by this paper
• Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

  2006cited by this paper
• Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization

  2006cited by this paper
• Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A Viruses Require Different Antigen Designs for the Induction of Optimal Protective Antibody Responses as Studied by Codon-Optimized HA DNA Vaccines

  2006cited by this paper
• Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

  2006cited by this paper
• Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

  2006cited by this paper
• Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.

  2006influential reference
• Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

  2006cited by this paper
• A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.

  2006cited by this paper
• The Cytoplasmic Tail of the Influenza A Virus M2 Protein Plays a Role in Viral Assembly

  2006cited by this paper
• An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.

  2006cited by this paper
• Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.

  2006cited by this paper
• Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.

  2006cited by this paper
• Virus-Like Particle Vaccine Conferred Complete Protection Against a Lethal Influenza Virus Challenge

  2005cited by this paper
• Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model.

  2005cited by this paper
• The Influenza A Virus M2 Cytoplasmic Tail Is Required for Infectious Virus Production and Efficient Genome Packaging

  2005cited by this paper
• Universal influenza A vaccine: optimization of M2-based constructs.

  2005cited by this paper
• Evolution of H5N1 Avian Influenza Viruses in Asia

  2005cited by this paper
• Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics.

  2005cited by this paper
• Attenuation of Equine Influenza Viruses through Truncations of the NS1 Protein

  2005cited by this paper
• The virosome concept for influenza vaccines.

  2005cited by this paper
• Highly Efficient Constant-Current Electroporation IncreasesIn Vivo Plasmid Expression

  2005cited by this paper
• The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.

  2005cited by this paper
• Adjuvant and antigen delivery properties of virosomes.

  2005cited by this paper
• Immunogenicity of Fowlpox Virus Expressing the Avian Influenza Virus H5 Gene (TROVAC AIV-H5) in Cats

  2005cited by this paper
• Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines.

  2005cited by this paper
• Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.

  2005influential reference
• Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

  2005cited by this paper
• Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine

  2005cited by this paper
• Virus-Like Particle (VLP) Vaccine Conferred Complete Protection against a Lethal Influenza Virus Challenge

  2005cited by this paper
• Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

  2005cited by this paper
• A review of vaccine research and development: Human acute respiratory infections

  2005cited by this paper
• Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

  2005cited by this paper
• Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus.

  2004cited by this paper
• Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity

  2004cited by this paper
• Immunogenicity and Protection Efficacy of Replication-Deficient Influenza A Viruses with Altered NS1 Genes

  2004cited by this paper
• Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines

  2004cited by this paper
• Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

  2004cited by this paper
• An Evaluation of Enforced Rapid Proteasomal Degradation as a Means of Enhancing Vaccine-Induced CTL Responses1

  2004cited by this paper
• Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003

  2004cited by this paper

• Novel Computational Method to Define RNA PSRs Explains Influenza A Virus Nucleotide Conservation

  2018cites this paper
• Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1.

  2016cites this paper
• Feasibility Analysis of p62 (SQSTM1)—Encoding DNA Vaccine as a Novel Cancer Immunotherapy

  2014cites this paper
• HUMAN INFLUENZA ( HUMAN FLU ) Human

  2013cites this paper
• Specific temperature-induced perturbations of secondary mRNA structures are associated with the cold-adapted temperature-sensitive phenotype of influenza A virus

  2012cites this paper
• The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development.

  2012cites this paper
• The evolution of influenza viruses

  2012cites this paper
• Parasite-Mediated Upregulation of NK Cell-Derived Gamma Interferon Protects against Severe Highly Pathogenic H5N1 Influenza Virus Infection

  2011cites this paper
• Findings from a household randomized controlled trial of hand washing and face masks to reduce influenza transmission in Bangkok, Thailand

  2011cites this paper
• Human Case Studies: Pandemic Influenza and Critical Limb Ischemia

  2011cites this paper
• Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target

  2010cites this paper
• Production of adenovirus vectors and their use as a delivery system for influenza vaccines

  2010cites this paper